Your session is about to expire
← Back to Search
Behavioral Intervention
Gamification for Alzheimer's Disease
N/A
Waitlist Available
Led By Ryan Greysen, MD, MHS, MA
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 week intervention period (weeks 1 - 12)
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if a fun game can help older adults walk more to prevent Alzheimer's. Participants set daily step goals and get support from a partner. The game aims to make walking a long-term habit.
Eligible Conditions
- Alzheimer's Disease
- Dementia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 12 week intervention period (weeks 1 - 12)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 week intervention period (weeks 1 - 12)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Mean Daily Steps From the Baseline Period to the End of the 12 Week Intervention Period.
Secondary study objectives
Change in Mean Daily Step Counts During the 6 Week Follow-up Period After the End of the Intervention Period Tracked by Fitbit Inspire Device.
Other study objectives
Change in Moderate-vigorous Physical Activity (MVPA) Minutes During the Baseline and Follow-up Period (Weeks 13-18).
Change in Moderate-vigorous Physical Activity Minutes (MVPA) During the Start of the Intervention Period Compared to Baseline Period.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: GamificationExperimental Treatment1 Intervention
Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 12-week intervention period.
At the end of the 12 week intervention period, participants will enter a 6 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design.
Group II: ControlActive Control1 Intervention
Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gamification
2019
Completed Phase 3
~3090
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,066 Previous Clinical Trials
42,712,669 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,766 Previous Clinical Trials
28,184,600 Total Patients Enrolled
Ryan Greysen, MD, MHS, MAPrincipal InvestigatorUniversity of Pennsylvania
4 Previous Clinical Trials
717 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger